既得C1阻害剤の欠乏による血管腫に対するデウクリクティバントの長期予防治療

Mats de Lange¹, Remy S Petersen¹, Lauré M Fijen¹

¹Amsterdam UMC, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam, the Netherlands.

The Journal of allergy and clinical immunology

|August 29, 2025

まとめ

デウクリクティバント延長放出錠剤は,既得C1阻害剤欠乏症 (AAE- C1INH) の患者で血管腫の発作を効果的に予防しました. この治療法では,長期間使用中の安全性に関する懸念はなく,このまれな疾患の管理に新しい選択肢を提供しました.

科学分野:

薬理学について
免疫学
希少疾患

背景:

取得したC1阻害剤欠乏症 (AAE- C1INH) は,ブラジキニンの過剰生産による再発性血管腫を引き起こす希少な疾患である.
B2受容体の抗体であるデウクリクティバントは,遺伝性血管腫の治療のために開発されています.
AAE- C1INH患者におけるデウクリクティバントの有効性が示された.

研究の目的:

AAE- C1INH患者における血管腫予防におけるデウクリクチバント延長放出錠剤の長期的な有効性と安全性を評価する.

主な方法:

AAE- C1INH患者で,デウクリクチバント 40 mg 延長放出錠を毎日投与したオープン・シングルアーム試験が行われました.
測定された主なアウトカムは,ベースラインと比較して28日あたりの血管腫発作の減少でした.

主要な成果:

4人のAAE- C1INH患者が登録され,3人は以前の試験から継続した.
患者の月間血管腫の発作は,治療開始時の平均1. 35から治療中に0. 01に大幅に減少しました.
フォローアップ期間 (563~612日) に関する有害事象は報告されなかった.

結論:

AAE- C1INH患者における血管腫の発作を予防する効果が顕著である.
長期予防療法としての可能性を示唆する安全性に関する懸念は認められませんでした.

キーワード:

C1 阻害剤の欠乏による既得血管腫血管腫ブラジキニンB2受容体デウクリクチバン長期的な予防

さらに関連する動画

07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.3K

03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

661

関連する概念動画

01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

01:19

Depolarizing Blockers: Pharmocokinetics

377

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

377

01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

1.3K

01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

253

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

253

01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...

関連する実験動画